APA (7th ed.) Citation

J, N., N, P., SW, K., Y, G., SM, L., G, M., . . . T, N. (2024). CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(20), 2393. https://doi.org/10.1200/JCO.23.02166

Chicago Style (17th ed.) Citation

J, Neal, et al. "CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 20 (2024): 2393. https://doi.org/10.1200/JCO.23.02166.

MLA (9th ed.) Citation

J, Neal, et al. "CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 20, 2024, p. 2393, https://doi.org/10.1200/JCO.23.02166.